Literature DB >> 24686315

Do genetic mutations and genotypes contribute to onychomycosis?

Aditya K Gupta1, Fiona C Simpson, William C Brintnell.   

Abstract

BACKGROUND: The variability in susceptibility to onychomycosis for individuals exposed to the same environmental risk factors raises the possibility that there may be individuals with a genetic predisposition to dermatophyte infection.
OBJECTIVE: To determine whether there are genetic mutations or genotypes which contribute to onychomycosis.
METHODS: The PubMed database was searched for examples of immune deficiencies resulting in dermatophyte infections.
RESULTS: There are mutations in the innate immune receptors Dectin-1 and its adaptor protein CARD9 which result in familial mucocutaneous infections. There are also specific human leukocyte antigen genotypes that are more common in individuals and families with a high prevalence of onychomycosis. In addition, some patients have been reported with insufficient levels of CD4+CD25+ regulatory T cells. These deficits impair a full innate and adaptive immune response and may result in chronic or recurrent infections.
CONCLUSIONS: There are documented mutations and genotypes that contribute to familial and individual susceptibility to onychomycosis.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24686315     DOI: 10.1159/000358586

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

Review 1.  Environmental and Genetic Factors on the Development of Onychomycosis.

Authors:  Cerise Adams; Evangelia Athanasoula; Woojung Lee; Nargiza Mahmudova; Tracey C Vlahovic
Journal:  J Fungi (Basel)       Date:  2015-08-31

Review 2.  Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials.

Authors:  Julianne M Falotico; Rebecca Lapides; Shari R Lipner
Journal:  J Fungi (Basel)       Date:  2022-03-09

3.  A Case Report of Majocchi's Granuloma Associated with Combined Therapy of Topical Steroids and Adalimumab.

Authors:  Wan-Yi Chou; Chih-Jung Hsu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.